Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
Why IGM Biosciences Stock Rocketed Higher Today
11:41am, Tuesday, 29'th Mar 2022
In addition to reporting its fourth-quarter results, the clinical-stage biotech announced a lucrative new collaboration deal with Sanofi.
IGM Biosciences Shares Surge After Oncology/Immunology Pact With Sanofi
08:02am, Tuesday, 29'th Mar 2022
Sanofi SA (NASDAQ: SNY) and IGM Biosciences Inc (NASDAQ: IGMS) have signed an exclusive worldwide collaboration agreement for IgM antibodies agonists against three oncology targets and three immun
Healthcare group Sanofi targets Dupixent peak sales of over 13 billion euros
12:58am, Tuesday, 29'th Mar 2022
French healthcare group Sanofi, which lagged rivals in the race for COVID-19 vaccines, raised on Tuesday its peak sales target for eczema-treatment product Dupixent to more than 13 billion euros ($14.
Pharma In Transition: Context And Opportunities
02:32pm, Monday, 28'th Mar 2022
The pending separation of consumer care businesses by pharmaceutical companies is understandable and may offer investment opportunities.
Sanofi halts new spending on non-essential drugs in Russia and Belarus
02:36pm, Wednesday, 23'rd Mar 2022
French drugmaker Sanofi on Wednesday said it would stop immediately any new spending not related to the supply of essential and life-changing medicines and vaccines in Russia, as well as in Belarus.
Sanofi, Seagen Collaborate For Antibody-Drug Conjugates Against Cancer Targets
01:27pm, Wednesday, 16'th Mar 2022 Benzinga
Sanofi SA (NASDAQ: SNY ) and Seagen Inc (NASDAQ: SGEN ) have announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi''s proprietary monoclonal antibody (mAb) technology and Seagen''s proprietary … Full story available on Benzinga.com
Sanofi, Seagen team up to develop antibody-drug conjugates for up to 3 cancer targets
10:58am, Wednesday, 16'th Mar 2022 Seeking Alpha
Sanofi (SNY) and Seagen (SGEN) signed an exclusive collaboration agreement to develop and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets.The…
Sanofi (SNY), Blackstone Ink Deal for Subcutaneous Sarclisa
10:32am, Wednesday, 16'th Mar 2022
Sanofi (SNY) is developing a subcutaneous formulation of its myeloma drug, Sarclisa. A pivotal study is expected to start in the second half of 2022.
Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
10:30am, Wednesday, 16'th Mar 2022 Business Wire
BOTHELL, Wash. & PARIS--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Sanofi today announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing a specific protein and Sanofi currently has
Sanofi, Blackstone ink €300M pact for subcutaneous Sarclisa for multiple myeloma
10:43am, Tuesday, 15'th Mar 2022 Seeking Alpha
Sanofi (SNY) and Blackstone (BX) entered a €300M collaboration to advance an innovative treatment for multiple myeloma ((MM)).The company said funds managed by Blackstone Life…
Sanofi's (SNY) Breast Cancer Candidate Misses Goal in Study
01:32pm, Monday, 14'th Mar 2022
Sanofi's (SNY) phase II AMEERA-3 study, investigating amcenestrant in ER+/HER2- advanced/metastatic breast cancer, fails to meet the primary endpoint.
Futures Fade As Yields Soar, Oil Slides And China Stocks Crater
12:15pm, Monday, 14'th Mar 2022 Zero Hedge
Futures Fade As Yields Soar, Oil Slides And China Stocks Crater US equity futures held on to modest gains overnight as the market desperately clung on to hope that the latest ceasefire talks between Russia and Ukraine which started on Monday, may yield results (clearly forgetting how the rug was pulled from under the market on Friday in an identical setup), which initially sent stocks higher especially in Europe, despite a surge in 10Y TSY yields to 2.10%, the highest since July 2019, two days ahead of the first Fed rate hike, and a complete collapse in Chinese stocks. And while U.S. index futures were still pointing to a positive open with negotiations between Russia and Ukraine set to continue, this gain is fading fast, with spoos now up just 0.5% after rising 1% earlier… ... as headlines from the Kremlin suggested that a ceasefire is the last thing on Putin''s mind. *KREMLIN: RUSSIA WILL REALIZE ALL ITS PLANS IN UKRAINE OPERATION *KREMLIN: UKRAINE OPERATION WILL BE COMPLETED ON SCHEDULE *KREMLIN: RUSSIA DIDN''T REQUEST CHINA MILITARY AID FOR OPERATION *KREMLIN: RUSSIA HAS RESOURCES NEEDED TO COMPLETE UKRAINE ACTION And while futures would normally be deep in the red by now, and will be shortly now that AAPL is at LOD...
Sanofi''s Stock Slides As Mid-Stage Amcenestrant Trial Suffers Setback In Breast Cancer
12:14pm, Monday, 14'th Mar 2022 Benzinga
Sanofi SA (NASDAQ: SNY ) stock slid after its drug candidate, amcenestrant, to fight a common type of breast cancer, failed to slow the progression of the disease in the Phase 2 AMEERA-3 trial. Results from the Phase 2 trial showed that the drug amcenestrant, given as a … Full story available on Benzinga.com
Why Sanofi Shares Are Trading Lower Today
12:14pm, Monday, 14'th Mar 2022 Benzinga
Sanofi SA (NASDAQ: SNY ) stock slid after … Full story available on Benzinga.com
Sanofi''s amcenestrant fails mid-stage study in advanced breast cancer
09:49am, Monday, 14'th Mar 2022 Seeking Alpha
Sanofi''s (SNY) oral medicine amcenestrant failed to meet the main goal of progression-free survival ((PFS)) in a phase 2 trial to treat patients with a type of advanced breast…
